Orlistat and calcium oxalate crystalluria: An association that needs consideration

Renal Failure

Volumn 32, Issue 8, 2010, Pages 1019-1021

  Ahmed, Mohamed H ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Calcium oxalate crystalluria; Kidney; Orlistat

Indexed keywords

CALCIUM OXALATE; TETRAHYDROLIPSTATIN;

ACUTE KIDNEY TUBULE NECROSIS; CALCIUM OXALATE STONE; CLINICAL TRIAL; CRYSTALLURIA; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE ABSORPTION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; URINALYSIS;

ANTI-OBESITY AGENTS; CALCIUM OXALATE; HUMANS; KIDNEY DISEASES; LACTONES; OBESITY;

EID: 77955937777     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.501929     Document Type: Review

References (19)

1. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565-1574.
2. Ahmed MH, Byrne CD. Metabolic syndrome, diabetes & CHD risk. In: Packard CJ, ed. The Year in Lipid Disorders. Oxford, UK: Clinical publishing; 2007:3-26.
3. Ahmed MH, Khalil A, Osman MM. Nitric oxide as treatment for an emerging epidemic of obesity-related glomerulopathy. Diabetes Res Clin Pract. 2006;74(2):207-208.
4. Hall JE, Jones DW, Kuo JJ, da SA, Tallam LS, Liu J. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep. 2003;5(5):386-392.
5. Wesson DE, Kurtzman NA, Frommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron. 1985;40(2):235-237.
6. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int. 2001;59(4):1498-1509.
7. Semins MJ, Shore AD, Makary MA, Magnuson T, Johns R, Matlaga BR. The association of increasing body mass index and kidney stone disease. J Urol. 2010;183(2):571-575.
8. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2009;11(3):188-195.
9. Bray GA. Lifestyle and pharmacological approaches to weight loss: Efficacy and safety. J Clin Endocrinol Metab. 2008;93(11 Suppl. 1):S81-S88.
10. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161.
11. MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van NM, Macdougall IC. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis. 2010;55(1):69-76.
12. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):927-949.
13. Lindsjo M. Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption. Scand J Urol Nephrol Suppl. 1989;119:1-53.
14. Ferraz RR, Tiselius HG, Heilberg IP. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int. 2004;66(2): 676-682.
15. Sarica K, Akarsu E, Erturhan S, Yagci F, Aktaran S, Altay B. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor. Obesity (Silver Spring). 2008;16(7):1579-1584.
16. Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100-107.
17. Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;71(4):430-432.
18. Karamadoukis L, Ludeman L, Williams AJ. Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis? Nephrol Dial Transplant. 2008;23(5): 1778-1779.
19. Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis. 2007;49(1):153-157.